Skip to main content

Peer Review reports

From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

Original Submission
4 Jan 2017 Submitted Original manuscript
21 Feb 2017 Reviewed Reviewer Report - Robert Moss
23 Feb 2017 Reviewed Reviewer Report - Wendong Liu
24 Mar 2017 Author responded Author comments - Teresa Kauf
Resubmission - Version 2
24 Mar 2017 Submitted Manuscript version 2
13 Apr 2017 Author responded Author comments - Teresa Kauf
Resubmission - Version 3
13 Apr 2017 Submitted Manuscript version 3
Publishing
18 Apr 2017 Editorially accepted
28 Apr 2017 Article published 10.1186/s12879-017-2408-7

You can find further information about peer review here.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us